Set to launch in Europe in early 2019, Flow will cost around and is designed to be used to reduce the effects of acute depression over an initial period of six weeks, with a follow up phase after ...

A total of 888 patients underwent randomization (447 patients in the PCI group and 441 in the medical-therapy group). At 5 years, the rate of the primary end point was lower in the PCI group than ...